Completed PHASE1 INTERVENTIONAL 1-arm NCT06390098

Positron Emission Tomography Study in Healthy Subjects to Determine the Relationship Between Plasma Concentration and Brain Target Occupancy of ASN51

A Phase 1, Open-Label, Positron Emission Tomography Study in Healthy Adult Subjects to Determine the Relationship Between Plasma Concentration and Brain Target Occupancy of ASN51 Following a Single Oral Dose

Sponsor: Asceneuron S.A.

Conditions Healthy Participants

Interventions ASN51

Updated 5 times since 2024 Last updated: May 7, 2025 Started: Aug 9, 2021 Primary completion: Oct 12, 2021 Completion: Oct 12, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06390098, this PHASE1 trial focuses on Healthy Participants and remains completed. Sponsored by Asceneuron S.A., it has been updated 5 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Jun 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Jun 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jun 2024 — Jul 2024 [monthly]

Completed PHASE1
May 2024 — Jun 2024 [monthly]

Completed PHASE1

First recorded

Aug 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Asceneuron S.A.
Hammersmith Medicines Research Invicro

Data source: Asceneuron S.A.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London, United Kingdom